Y Intercept Hong Kong Ltd Boosts Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Y Intercept Hong Kong Ltd boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 111.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,148 shares of the biotechnology company’s stock after purchasing an additional 7,970 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Biogen were worth $2,316,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. MONECO Advisors LLC acquired a new stake in shares of Biogen in the fourth quarter worth $205,000. Howard Capital Management Inc. increased its position in shares of Biogen by 3.4% in the fourth quarter. Howard Capital Management Inc. now owns 4,602 shares of the biotechnology company’s stock worth $704,000 after acquiring an additional 153 shares in the last quarter. Denver PWM LLC increased its position in shares of Biogen by 43.5% in the fourth quarter. Denver PWM LLC now owns 538 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 163 shares in the last quarter. Callan Capital LLC increased its position in shares of Biogen by 87.8% in the fourth quarter. Callan Capital LLC now owns 2,075 shares of the biotechnology company’s stock worth $317,000 after acquiring an additional 970 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Biogen by 5.7% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,612 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 87 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Up 0.4 %

Biogen stock opened at $141.27 on Tuesday. The firm’s 50-day moving average is $144.97 and its 200-day moving average is $169.97. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen Inc. has a 1 year low of $128.51 and a 1 year high of $238.00. The company has a market cap of $20.68 billion, a P/E ratio of 12.62, a PEG ratio of 1.51 and a beta of -0.08.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, equities analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Analyst Ratings Changes

BIIB has been the subject of several recent research reports. Barclays dropped their price objective on shares of Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a research report on Thursday, October 31st. Bank of America reissued a “neutral” rating and issued a $178.00 price objective on shares of Biogen in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Biogen in a report on Thursday, February 13th. Sanford C. Bernstein began coverage on shares of Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 price target for the company. Finally, Wolfe Research began coverage on shares of Biogen in a report on Friday, November 15th. They set a “peer perform” rating for the company. Seventeen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $213.33.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.